Experience and prognostic analysis with avelumab switch maintenance treatment in metastatic urothelial carcinoma.

Teruki IsobeTaku NaikiYosuke SugiyamaAya Naiki-ItoTakashi NagaiToshiki EtaniKeitaro IidaYusuke NodaNobuhiko ShimizuMaria AokiMasakazu GondaToshiharu MorikawaRika BannoHiroki KubotaRyosuke AndoNoriyasu KawaiTakahiro Yasui

Published in: Oncology (2024)

In mUC, avelumab maintenance prolonged OS within tolerable safety profiles. GNRI sustainability may be used as biomarker to predict being Ave-suitable.

Keyphrases

small cell lung cancer
combination therapy
replacement therapy